Oisin Biotechnologies is a longevity therapeutics platform company focused on creating genetic medicines to combat a variety of age related diseases. When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisín Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.
External link for Oisin Biotechnologies
800 5th Avenue
Suite 4100
Seattle, WASHINGTON (WA) 98104, US
Oisin Biotechnologies reposted this
We are pleased to welcome Oisin Biotechnologies to the AbbVie #Ventures family of #portfolio companies. The funding will enable the value-inflecting progression of ongoing preclinical programs that eliminate unwanted fat cells and build muscle mass to address age-related diseases. Welcome, Matthew Scholz and Team Oisin! #innovationtakesallofus Danjuma Q. Darin Messina
We’re thrilled to announce the first close in a $15 million Series A financing round that supports development of our pipeline of therapies for age-related diseases as we bring them closer to the clinic. We’re grateful for the support of AbbVie Ventures, which led the first close, and are looking forward to working with Danjuma Q. and Darin Messina as they join our Board of Directors and Scientific Advisory Board, respectively. This is an important milestone for Oisín. It comes as the medical community sees an increased appetite for new approaches to addressing age-related disease — including a growing interest in treatments that can potentially mitigate some of the challenges that come with the blockbuster GLP-1s. With a committed team, tight focus, and promising platform, everyone at Oisín is excited to make the most of the opportunities ahead of us. For more information on today’s news, see our press release: https://lnkd.in/g3ihEk_S
Oisin CEO, Matthew Scholz, speaking at the excellent Rejuvenation Startup Summit 2024 in Berlin. Michael Greve, Frank Schueler, Forever Healthy
Oisin CEO, Matthew Scholz, presenting at this year’s Life Science Innovation Northwest conference in Seattle, WA.
Oisin’s CEO Matthew Scholz was recently interviewed by BioInsights Senior Editor David McCall for the launch issue of Nucleic Acid Insights. Take a look to learn more about how we’re using the Entos Pharmaceuticals' Proteo-Lipid Vehicle (PLV) platform to develop genetic medicines for improved health and longevity! They discuss our unique approach, the need to develop scalable therapies to tackle the monumental challenge of aging populations, and where we see the field going in the future. https://lnkd.in/gyC3ruNr #geneticmedicine #longevity #healthspan #agingresearch #dna #nucleicacid #nonviralvectors #genetherapy #plv
Come to Dublin August 17-20 to hear our CEO, Matthew Scholz, share the latest developments from Oisin Biotechnologies at the Longevity Summit Dublin!
I’m excited to be returning to Dublin next month to join a stellar lineup of longevity science visionaries Longevity Summit Dublin. Thanks to Aubrey de Grey, Martin O 'Dea, and the Longevity Escape Velocity (LEV) Foundation team for putting together this fantastic event! Register online today and learn how Oisin and others are advancing this life-changing field. https://lnkd.in/gqiayZUU Oisin Biotechnologies #longevity #longevityscience Entos Pharmaceuticals